Cingulate's Ctx-1301 Provides Active Day Coverage

2025 0:54
Synopsis
Cingulate's (NASDAQ: CING) CEO Dr. Shane Schaffer shares how the company is developing CTx-1301 for ADHD and how this ...

You Might Also Like

CTx-1301 – Once Daily Entire Active Day Coverage 12:00
Ctx-1301 – Once Daily Entire Active Day Coverage
2026
Cingulate's Precision Timed Release Technology 0:32
Cingulate's Precision Timed Release Technology
2025
Final Stages of Development for Cingulate's CTx-1301 7:57
Final Stages Of Development For Cingulate's Ctx-1301
2025
CTX 1301 A New ADHD Medication 0:55
Ctx 1301 A New Adhd Medication
2026
Why Will Patients Be Willing to Pay for CTx-1301? 1:40
Why Will Patients Be Willing To Pay For Ctx-1301?
2025
Brief Summary of Adult CTx 1301 Data 1:47
Brief Summary Of Adult Ctx 1301 Data
2026
CTx 1301 History 1:57
Ctx 1301 History
2026
Pediatric Trial Shows Efficacy for CTx-1301 1:43
Pediatric Trial Shows Efficacy For Ctx-1301
2026
Cingulate's CEO Talks ADHD Symptoms and Disorder Dynamics 10:06
Cingulate's Ceo Talks Adhd Symptoms And Disorder Dynamics
2025
Cingulate's Precision Timed Release Technology 12:13
Cingulate's Precision Timed Release Technology
2025
Difficult Times to Treat ADHD 1:55
Difficult Times To Treat Adhd
2026
Download Options
Choose a download method below. All links open in new tabs.
Service Features Action
SaveFrom
MP4 & MP3 • HD Quality • Browser Extension Available
Download
Security Notice: These are third-party services. We recommend using antivirus software and being cautious of pop-up ads.